

( (S (SBAR-ADV As
	       (S (NP-SBJ (NP (NP Georgia-Pacific 's)
			      bid)
			  (PP for
			      (NP Great Northern Nekoosa)))
		  (VP has
		      (VP shown
			  (SBAR 0
				(S *?*))))))
     ,
     (NP-SBJ uninvited takeovers)
     (VP are
	 (ADVP still)
	 (ADJP-PRD alive)
	 (PP despite
	     (NP (NP premature reports)
		 (PP of
		     (NP their demise)))))
     .))
( (S (ADVP Therefore)
     ,
     (NP-SBJ-1 (NP the debate)
	       (PP about
		   (NP poison pills)))
     (VP will
         (VP continue
             (S (NP-SBJ *-1)
                (VP to
                    (VP rage
                        (PP-LOC in
				(NP (NP (NP the boardrooms)
					(PP of
					    (NP corporations)))
				    and
				    (NP (NP the halls)
					(PP of
					    (NP academia))))))))))
     .))
( (S (SBAR-ADV Although
	       (S (NP-SBJ poison pills)
		  (VP come
		      (PP-MNR in
			      (NP different colors and shapes)))))
     ,
     (NP-SBJ they)
     (ADVP-TMP usually)
     (VP give
         (NP current shareholders)
         (NP the right
             (S (NP-SBJ *)
                (VP to
                    (VP buy
                        (NP (NP more stock)
                            (PP of
                                (NP their corporation)))
                        (PP-CLR at
				(NP a large discount))
			(SBAR-ADV (SBAR if
					(S (NP-SBJ certain events)
					   (VP occur)))
				  --
				  (PRN (ADVP typically)
				       ,
				       (SBAR if
					     (S (NP-SBJ a hostile bidder)
						(VP acquires
						    (NP (NP more)
							(PP than
							    (NP (NP a specified percentage)
								(PP of
								    (NP (NP the corporation 's)
									stock)))))))))))))))
     .))
( (S (ADVP However)
     ,
     (NP-SBJ-170 these discount purchase rights)
     (VP may
         (ADVP generally)
         (VP be
             (VP redeemed
                 (NP *-170)
                 (PP-CLR at
			 (NP a nominal cost))
                 (PP by
                     (NP-LGS (NP the corporation 's)
			     directors))
		 (SBAR-ADV if
			   (S (NP-SBJ they)
			      (VP approve
				  (PP-CLR of
					  (NP a bidder))))))))
     .))
( (S (NP-SBJ (NP Supporters)
             (PP of
                 (NP poison pills)))
     (VP argue
         (SBAR that
               (S (NP-SBJ their adoption)
                  (VP forces
		      (S (NP-SBJ bidders)
			 (VP to
                             (VP negotiate
                                 (PP-CLR with
					 (NP (NP (NP a corporation 's)
						 directors)
					     ,
					     (SBAR (WHNP-185 who)
						   (S (NP-SBJ-1 *T*-185)
						      (VP are
							  (ADVP thereby)
							  (VP put
							      (NP *-1)
							      (PP-PUT in
								      (NP (NP a better position)
									  (SBAR (WHADVP-2 0)
										(S (NP-SBJ *)
										   (VP to
										       (VP pursue
											   (NP (NP the long-term interests)
											       (PP of
												   (NP the corporation)))
											   (ADVP-LOC *T*-2))))))))))))))))))))
     .))
( (S (NP-SBJ (NP Recent studies)
             (PP by
                 (NP Georgeson & Co.)))
     (VP conclude
         (SBAR that
               (S (NP-SBJ (NP corporations)
                          (PP with
                              (NP poison pills)))
                  (VP have
                      (VP experienced
                          (NP (NP greater stock-price appreciation)
                              (PP than
                                  (NP (NP corporations)
                                      (PP without
                                          (NP poison pills)))))
			  (PP-TMP during
				  (NP the past few years)))))))
     .))
( (S (NP-SBJ (NP Critics)
             (PP of
                 (NP poison pills)))
     (VP argue
         (SBAR that
               (S (NP-SBJ-1 they)
                  (VP harm
                      (NP shareholders)
                      (PP-MNR (PP by
				  (S-NOM (NP-SBJ *-1)
					 (VP letting
					     (S (NP-SBJ corporate management)
						(VP defeat
						    (NP (NP takeover bids)
							(PP at
							    (NP premium prices))))))))
			      and
			      (PP by
				  (S-NOM (NP-SBJ *-1)
					 (VP deterring
					     (NP-2 premium bids)
					     (PP-CLR from
						     (S-NOM (NP-SBJ-171 *-2)
							    (ADVP-TMP ever)
							    (VP being
								(VP made
								    (NP *-171)
								    (PP-DTV to
									    (NP shareholders))))))))))))))
     .))
( (S (NP-SBJ-172 These critics)
     (VP are
         (VP backed
             (NP *-172)
             (PP by
                 (NP-LGS (NP several academic studies)
			 (VP showing
			     (SBAR that
				   (S (NP-SBJ (NP the adoption)
					      (PP of
						  (NP poison pills)))
				      (VP reduces
					  (NP shareholder values)
					  (PP-TMP (CONJP not merely)
						  (PP in
						      (NP the short run))
						  ,
						  (CONJP but also)
						  (PP over
						      (NP longer periods)))))))))))
     .))
( (S (NP-SBJ (NP Institutional investors)
             (SBAR (WHNP-186 that)
                   (S (NP-SBJ *T*-186)
                      (VP must
                          (VP evaluate
                              (NP poison pills)
			      (PP-TMP on
				      (NP a regular basis)))))))
     (VP are
         (VP interested
	     (ADVP (ADVP less)
		   (PP *ICH*-1))
	     (PP-CLR in
		     (NP this general debate))
	     (PP-1 than
		   (PP in
		       (NP (NP the answers)
			   (PP to
			       (NP (NP specific questions)
				   (PP about
				       (NP (NP the corporation)
					   (VP issuing
					       (NP the pill)))))))))))
     .))
( (SQ Does
      (NP-SBJ this corporation)
      (VP have
          (NP (NP a high-quality management team)
              (PP with
                  (NP a good track record))))
      ?))
( (SQ (SQ Does
          (NP-SBJ this team)
          (VP have
              (NP (NP a viable strategy)
                  (PP for
                      (S-NOM (NP-SBJ *)
			     (VP improving
				 (NP shareholder values)))))))
      , and
      (SQ does
          (NP-SBJ this strategy)
          (VP require
              (NP implementation)
              (PP-TMP over
		      (NP an extended period))))
      ?))
( (SQ Will
      (NP-SBJ (NP the adoption)
	      (PP of
		  (NP (NP this particular form)
		      (PP of
			  (NP a poison pill)))))
      (VP (ADVP-MNR significantly)
          improve
          (NP the chances
              (SBAR for
		    (S (NP-SBJ management)
		       (VP to
			   (VP carry
			       (PRT out)
			       (NP this strategy)))))))
      ?))
( (S (SBAR-ADV If
	       (S (NP-SBJ (NP the answers)
			  (PP to
			      (NP these questions)))
		  (VP are
		      (ADJP-PRD affirmative))))
     ,
     (ADVP then)
     (NP-SBJ-1 institutional investors)
     (VP are
         (ADJP-PRD likely
		   (S (NP-SBJ *-1)
		      (VP to
			  (VP be
			      (ADJP-PRD favorably disposed
					(PP toward
					    (NP a specific poison pill))))))))
     .))
( (S (ADVP However)
     ,
     (NP-SBJ the problem)
     (VP is
         (SBAR-PRD that
		   (S (SBAR-TMP once
				(S (NP-SBJ-173 most poison pills)
				   (VP are
				       (VP adopted
					   (NP *-173)))))
		      ,
		      (NP-SBJ they)
		      (VP survive
			  (ADVP-TMP forever)))))
     .))
( (SBARQ (SBAR-ADV Although
		   (S (NP-SBJ the current management team)
		      (VP may
			  (VP be
			      (ADJP-PRD outstanding)))))
	 ,
	 (WHNP-187 who)
	 (SQ will
	     (NP-SBJ *T*-187)
	     (VP be
		 (NP-PRD the CEO)
		 (PP-TMP in
			 (NP 10 years))))
	 ?))
( (SBARQ (SBAR-ADV Although
		   (S (NP-SBJ the five-year strategy)
		      (VP may
			  (VP be
			      (ADJP-PRD excellent)))))
	 ,
	 (WHNP-188 what)
	 (SQ will
	     (NP-SBJ *T*-188)
	     (VP be
		 (NP-PRD the strategy)
		 (PP-TMP in
			 (NP 25 years))))
	 ?))
( (S (NP-SBJ (NP The solution)
             (PP to
                 (NP this problem)))
     (VP is
         (NP-PRD a time-limited poison pill))
     .))
( (S (NP-SBJ The limit)
     (VP could
	 (VP range
	     (PP-CLR (PP from
			 (NP three years))
		     (PP to
			 (NP seven years)))
	     ,
	     (PP depending
		 (PP on
		     (NP (NP (NP the composition)
			     (PP of
				 (NP the management team)))
			 and
			 (NP (NP the nature)
			     (PP of
				 (NP its strategic plan))))))))
     .))
( (S (PP-TMP At
	     (NP (NP the end)
		 (PP of
		     (NP this period))))
     ,
     (NP-SBJ-174 the poison pill)
     (VP would
	 (VP be
	     (VP eliminated
		 (NP *-174)
		 (ADVP-MNR automatically)
		 ,
		 (SBAR-ADV unless
			   (S (NP-SBJ-175 a new poison pill)
			      (VP were
				  (VP approved
				      (NP *-175)
				      (PP by
					  (NP-LGS (NP the then-current shareholders)
						  ,
						  (SBAR (WHNP-189 who)
							(S (NP-SBJ *T*-189)
							   (VP would
							       (VP have
								   (NP an opportunity
								       (S (NP-SBJ *)
									  (VP to
									      (VP evaluate
										  (NP (NP the corporation 's)
										      strategy and management team)))))
								   (PP-TMP at
									   (NP that time)))))))))))))))
     .))
( (S (NP-SBJ (NP One rare example)
             (PP of
                 (NP a time-limited poison pill)))
     (VP is
         (NP-PRD (NP the shareholder rights plan)
		 (VP adopted
		     (NP *)
		     (PP by
			 (NP-LGS Pennzoil))
		     (NP-TMP last year)
		     (SBAR-TMP after
			       (S (NP-SBJ it)
				  (VP received
				      (NP a huge litigation settlement)
				      (PP-CLR from
					      (NP Texaco))))))))
     .))
( (S (NP-SBJ (NP Pennzoil 's)
             poison pill)
     (VP covers
         (NP five years)
	 (SBAR-PRP in order
		   (S (NP-SBJ *)
		      (VP to
			  (VP give
			      (NP current management)
			      (NP (NP enough time)
				  (SBAR (WHADVP-1 0)
					(S (NP-SBJ *)
					   (VP to
					       (VP put
						   (NP these proceeds)
						   (PP-CLR to
							   (NP work))
						   (PP-MNR in
							   (NP a prudent manner))
						   (ADVP-MNR *T*-1)))))))))))
     .))
( (S (NP-SBJ Another interesting example)
     (VP is
         (NP-PRD (NP the poison pill)
		 (VP adopted
		     (NP *)
		     (ADVP-TMP recently)
		     (PP by
			 (NP-LGS (NP Pittsburgh-based National Intergroup Inc.)
				 ,
				 (NP a diversified holding company))))))
     .))
( (S (NP-SBJ-1 (NP The
		   (NAC State
			(PP of
			    (NP Wisconsin)))
		   Investment Board)
	       ,
	       (SBAR (WHNP-190 which)
		     (S (NP-SBJ *T*-190)
			(VP owned
			    (NP (NP (QP about 7) %)
				(PP of
				    (NP (NP the company 's)
					voting stock))))))
	       ,)
     (VP worked
         (PP with
	     (NP management))
         (S-PRP-CLR (NP-SBJ *-1)
		    (VP to
			(VP devise
			    (NP a time-limited poison pill)))))
     .))
( (S (NP-SBJ-1 This pill)
     (VP (ADVP automatically)
	 expires
	 (PP-TMP after
		 (NP three years))
	 (SBAR-ADV unless
		   (S (NP-SBJ-2 *-1)
		      (VP continued
			  (NP *-2)
			  (PP by
			      (NP-LGS (NP a vote)
				      (PP of
					  (NP the shareholders))))))))
     .))
( (S (NP-SBJ (NP The attitude)
             (PP of
                 (NP the Wisconsin Investment Board)))
     (VP reflects
         (NP (NP a growing receptivity)
	     (PP to
		 (NP time-limited poison pills))
	     (PP on
		 (NP (NP the part)
		     (PP of
			 (NP institutional investors)))))
	 ,
	 (SBAR-ADV as
		   (S (NP-SBJ-1 *)
		      (VP shown
			  (NP *-1)
			  (PP by
			      (NP-LGS (NP (NP the discussions)
					  (PP-LOC at
						  (NP (NP recent meetings)
						      (PP of
							  (NP (NP the Council)
							      (PP of
								  (NP Institutional Investors)))))))
				      and
				      (NP (NP my informal survey)
					  (PP of
					      (NP (NP several retirement plans)
						  (PP with
						      (NP large stock positions)))))))))))
     .))
( (S (NP-SBJ (NP (ADJP More widespread)
		 time limits)
             (PP on
                 (NP poison pills)))
     (VP would
         (VP allow
	     (S (NP-SBJ shareholders)
                (VP to
                    (VP evaluate
                        (NP a specific poison pill)
                        (PP within
                            (NP (NP the context)
                                (PP of
                                    (NP (NP a specific management team 's)
                                        strategy)))))))))
     .))
( (S (NP-SBJ-1 Such concrete analysis)
     (VP is
         (ADJP-PRD likely
		   (S (NP-SBJ *-1)
		      (VP to
			  (VP lead
			      (PP-DIR to
				      (NP (NP (ADJP more fruitful)
					      dialogue)
					  (PP between
					      (NP management
						  and
						  shareholders))
					  (PP than
					      (NP (NP the abstract debate)
						  (PP about
						      (NP poison pills)))))))))))
     .))
( (S (NP-SBJ Mr. Pozen)
     (VP is
         (NP-PRD (NP (NP the general counsel)
		     and
		     (NP a managing director))
		 (PP of
		     (NP (NP Fidelity Investments)
			 (PP-LOC in
				 (NP Boston))))))
     .))
